Avastin filed for lung cancer in Japan
This article was originally published in Scrip
Executive Summary
Chugai (Roche) has filed a submission in Japan for the approval of Avastin (bevacizumab) for the additional indication of non-small cell lung cancer. The application is for the first-line treatment of non-squamous advanced or recurrent disease in combination with standard platinum-based therapy, as approved in the US in 2006 and Europe last year. The VEGF-targeting antibody was approved for non-resectable advanced or recurrent colorectal cancer in Japan in April 2007. Chugai noted that the incidence of lung cancer in the country was forecast to rise to around 99,000 cases in 2010, and that NSCLC was already the leading cause of local cancer deaths.
You may also be interested in...
Quick Listen: Scrip's Five Must-Know Things
In this week's podcast edition of Five Must-Know Things: the shifting sands of pharma R&D; big pharma oncology strategies; semaglutide’s promise in heart failure; AstraZeneca looks to multiple cancer modalities; and an interview with Astellas’s chief strategy officer.
Quick Listen: Scrip's Five Must-Know Things
In this week's podcast edition of Five Must-Know Things: Genmab buys into ADCs; Roivant set to take on AbbVie in uveitis; Ipsen signs firs ADC pact; South Korea looks to build biotech momentum; and the end of the road for Acorda.
Quick Listen: Scrip's Five Must-Know Things
In this week's podcast edition of Five Must-Know Things: Merck & Co progresses cardiovascular strategy; Novo purchase builds heart failure presence; CRL setbacks for Regeneron; ITF faces challenging Duchenne field; and AbbVie needs to freshen up.